Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure

Masatake Kobayashi, Adriaan A. Voors, Wouter Ouwerkerk, Kevin Duarte, Nicolas Girerd, Patrick Rossignol, Marco Metra, Chim C. Lang, Leong L. Ng, Gerasimos Filippatos, Kenneth Dickstein, Dirk J. van Veldhuisen, Faiez Zannad, João Pedro Ferreira (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

4 Downloads (Pure)

Abstract

Background: Achieving target doses of angiotensin-converting-enzyme inhibitor/angiotensin-receptor blockers (ACEi/ARB) and beta-blockers in heart failure with reduced ejection fraction (HFrEF) is often underperformed. In BIOlogy Study to TAilored Treatment in chronic heart failure (BIOSTAT-CHF) study, many patients were not up-titrated for which no clear reason was reported. Therefore, we hypothesized that perceived-risk profile might influence treatment optimization.

Methods: We studied 2100 patients with HFrEF (LVEF≤40%) to compare the clinical characteristics and adverse events associated with treatment up-titration (after a 3-month titration protocol) between; a) patients not reaching target doses for unclear reason; b) patients not reaching target doses due to symptoms and/or side effects; c) patients reaching target doses.

Results: For ACEi/ARB, (a), (b) and (c) was observed in 51.3%, 25.9% and 22.7% of patients, respectively. For beta-blockers, (a), (b) and (c) was observed in 67.5%, 20.2% and 12.3% of patients, respectively. By multinomial logistic regression analysis for ACEi/ARB, patients in group (a) and (b) had lower blood pressure and poorer renal function, and patients in group (a) were older and had lower ejection fraction. For beta-blockers, patients in group (a) and (b) had more severe congestion and lower heart rate. At 9 months, adverse events (i.e., hypotension, bradycardia, renal impairment, and hyperkalemia) occurred similarly among the three groups.

Conclusions: Patients in whom clinicians did not give a reason why up-titration was missed were older and had more co-morbidities. Patients in whom up-titration was achieved did not have excess adverse events. However, from these observational findings, the pattern of subsequent adverse events among patients in whom up-titration was missed cannot be determined.

Original languageEnglish
Pages (from-to)780-788
Number of pages9
JournalClinical Cardiology
Volume44
Issue number6
Early online date7 May 2021
DOIs
Publication statusPublished - Jun 2021

Keywords

  • ACE-inhibitor
  • adverse effects
  • ARB
  • beta-blocker
  • treatment up-titration

Fingerprint

Dive into the research topics of 'Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure'. Together they form a unique fingerprint.

Cite this